Pharsight

Oravig generic

Oravig is an antifungal medication owned by Galt Pharms. It contains miconazole and was authorised for market use on 16th April, 2010. The medication comes in a tablet or buccal dosage form.

When will Oravig generic be available?

A generic version of Oravig may become available after 11th September, 2022. This projected release date is contingent upon the expiration of the last patent, 'Prolonged release bioadhesive therapeutic systems (US7651698, US6916485, US8518442)', on the same date.

Oravig uses

Oravig is primarily used as a treatment for oropharyngeal candidiasis. Its effectiveness is due to the active ingredient, miconazole which stops the growth of fungus.

Oravig patent expiration

Oravig currently holds three patents, all due to expire on September 11, 2022. These patents are all titled 'Prolonged release bioadhesive therapeutic systems'. The expiration of these patents will potentially allow for the creation of Oravig generics. Below are the details of the patents:

Oravig dosage

Want to ask something?